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We used bone marrow/liver/thymus (BLT) humanized mice to establish the effect of semen on vaginal HIV infection and on the
efficacy of topically applied maraviroc. Our results demonstrate that vaginal transmission of cell-free HIV occurs efficiently in
the presence of semen and that topically applied maraviroc efficiently prevents HIV transmission in the presence of semen. We
also show that semen has no significant effect on the transmission of transmitted/founder viruses or cell-associated viruses.
Most new HIV infections are transmitted heterosexually (1).Women represent about half of all people living with HIV
worldwide and more than half (58%) of HIV-positive individuals
in sub-Saharan Africa (2). HIV is one of the leading causes of
death among women of reproductive age. Gender inequalities,
differential access to services, and sexual violence increase wom-
en’s vulnerability to HIV, and women, especially younger women,
are biologically more susceptible to HIV (2). Therefore, there is an
urgent need for effective interventions to prevent HIV transmis-
sion. Semen is second only to blood in the concentration of virus
present per unit volume (3). Sexual intercourse (vaginal and anal)
is a high-risk practice for HIV transmission. Thus, there is an
urgent need to better understand the potential role semen plays in
HIV transmission. This study sought to clarify this role through
the use of in vitro as well as extensive in vivo experimentation in the
bone marrow/liver/thymus (BLT) humanized mouse model.
Semen does not affect HIV-1 infectivity in vitro. The majority
of sexual exposures to HIV occur in the presence of semen. In
order to begin to assess the potential impact of semen on HIV-1
mucosal transmission, we used a well-established quantitative in
vitro assay based on the indicator cell line TZM-bl. Cells were
exposed to either virus alone or virus in the presence of semen.
The semen was obtained from Lee Biosolutions and is a pool of 17
repeat and characterized donors (kindly provided by the Compre-
hensive Resources for HIV Microbicides and Biomedical Preven-
tion). Infection was then determined as the amount of luciferase
activity produced by the infected cells 48 h after exposure. Our
results indicate that under our in vitro experimental conditions,
semen has no discernible effect on HIV infection (see Fig. S1 in the
supplemental material).
BLT humanized mice for the in vivo evaluation of the effect
of semen on vaginal HIV-1 transmission. Currently, humanized
mice represent the only in vivo model in which vaginal HIV-1
transmission can be studied. BLT humanized mice have been
shown to recapitulate key aspects of vaginal HIV-1 infection and
as such represent an excellent model to evaluate the effect of hu-
man semen on HIV-1 transmission (4–10). In order to establish
the effect of semen on HIV transmission, BLT humanized mice
were constructed, and the levels of human cells in their peripheral
blood were determined prior to exposure. The average level of
human (CD45) cells in the peripheral blood of mice used for the
experiments described in this article was 72%  12.5% (mean 
standard deviation [SD]). The majority of the human cells in
these mice were CD3 (60.8%  16.3%) and expressed CD4 on
their cell surface (80.6%  7.6%). Mice were maintained under
specific-pathogen-free conditions by the Division of Labora-
tory Animal Medicine, and all experiments were conducted
after review and approval by the Institutional Animal Care and
Use Committee at the University of North Carolina at Chapel
Hill.
Effect of semen on vaginal cell-free HIV-1 transmission and
on the protective effect of topically administered maraviroc.
Having established that mixing virus with semen has no effect on
its infectivity in vitro, we proceeded to evaluate the in vivo effect of
semen on HIV transmission and on the protective effect of a top-
ical microbicide using BLT humanized mice. For this purpose,
BLT humanized mice (n  9) were exposed to HIV-1JR-CSF (7 
105 tissue culture infectious units [TCIU]) in the presence of se-
men (50%). Control mice (n  6) were exposed to virus in the
absence of semen (vehicle). In addition, BLT humanized mice
(n  6) were treated with a single dose of topical maraviroc (10 l
of a 5 mM solution) and exposed to virus in semen (10 l). Mice
were monitored longitudinally for the presence of plasma viral
RNA as an indication of HIV-1 transmission. In the presence of
semen, 6/9 mice became infected after a single exposure to virus,
as determined by plasma viral load analysis (Fig. 1). In the absence
of semen, 5/6 mice became infected, as determined by the pres-
ence of viral RNA in plasma (Fig. 1). Therefore, there was no
statistical difference between the rates of transmission observed in
the presence or absence of human semen (P  0.29). Consistent
with previous reports using a different humanized mouse model
indicating the effectiveness of maraviroc at preventing HIV-1
transmission in humanized mice (although in the absence of hu-
man semen) (11), none of the animals treated with maraviroc
prior to exposure to virus in the presence of semen showed evi-
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dence of viral RNA in plasma (P  0.01) (Fig. 1). This is especially
striking in light of a recent study published by Zirafi et al. that
showed a reduced efficacy of many microbicides in the presence of
semen, with the exception of maraviroc (12). The sustained effi-
cacy of maraviroc in the presence of semen could be due in part to
the fact that maraviroc’s mode of action is different from those of
the majority of other microbicides, which act on the virus instead
of a host protein. Lack of transmission was documented by the
absence of DNA in the tissues analyzed from all of the treated
animals analyzed (Table 1). These results demonstrate that the
presence of human semen does not influence the effectiveness of
topically administered maraviroc at preventing vaginal HIV-1 in-
fection. Together these results also demonstrate the utility of the
BLT humanized mouse model for the evaluation of the effect of
semen on HIV transmission.
Human semen does not affect vaginal infection of BLT hu-
manized mice with HIV-1CH040, a T/F virus. HIV infection after
vaginal exposure is established by one or a few viruses that have
been designated transmitted/founder (T/F) viruses (13–16). In
order to determine if semen had an effect on vaginal infection of
BLT humanized mice by a T/F virus, animals were vaginally ex-
posed to HIV-1CH040 (3.5  10
5 TCIU) in the presence (50%)
(n  6) or in the absence (n  4) of semen (vehicle). In both cases,
all of the exposed mice showed readily detectable levels of viral
RNA in plasma after a single exposure to virus (Fig. 2). Infection
with HIV-1CH040 resulted in a slight drop in CD4
 T cell levels
(Fig. 2). Log-rank (Mantel-Cox) analysis of these data indicated
that the presence of semen had no deleterious effect on the trans-
mission of HIV-1CH040 in BLT humanized mice (Fig. 2).
Effect of semen on vaginal transmission of cell-associated
HIV-1JR-CSF. Since human semen contains both cell-free and cell-
associated HIV, we sought to determine if semen had an effect on
the transmission of cell-associated HIV-1JR-CSF. For this purpose,
we exposed BLT humanized mice to human peripheral blood
mononuclear cells (PBMCs) infected with HIV-1JR-CSF (1  10
5
p24-positive cells by flow cytometry) in the presence (n  4) or in
the absence (n  4) of human semen (50%). In the presence of
semen, viral RNA was readily detectable in 3/4 exposed mice (Fig.
3). In the absence of semen, viral RNA was readily detected in the
plasma of 4/4 of exposed BLT humanized mice (Fig. 3). Log rank
(Mantel-Cox) analysis of these data indicates that the presence of
semen had no effect on the transmission of cell-associated HIV-1
(Fig. 3).
Even though most sexually acquired cases of HIV-1 occur in
the presence of semen, the role semen plays in HIV-1 transmission
has been controversial. Many in vitro studies have shown that
semen enhances infection (17, 18). Most commonly, the enhanc-
ing effect observed with exposure to semen is attributed to cat-
ionic polypeptides capable of forming amyloid fibrils; also known
as semen-derived enhancer of virus infection (SEVI). A study
published by Münch et al. showed that peptide fragments of pros-
tatic acid phosphatase form amyloid fibrils augment a virion’s
ability to bind to target cells (18). However, this effect has only
been observed in vitro (19). Conversely, seminal plasma has been
shown to interfere with a variety of mechanisms that facilitate viral
uptake and dissemination (20). To date, the role of semen in
HIV-1 transmission remains the subject of much debate. As the
majority of studies aimed at elucidating its possible role have been
conducted in vitro, it is evident that there is a need for compre-
hensive in vivo analysis. Furthermore, as the majority of sexual
exposures to HIV occur in the presence of semen, in vivo analyses
of the efficacy of preexposure prophylaxis approaches should be
tested in the presence of semen.
In this article, we present an evaluation of the effect of semen
on vaginal HIV-1 transmission using BLT humanized mice, a val-
idated model for the study of mucosal HIV-1 transmission and
prevention. The BLT humanized mouse model has been previ-
ously characterized as an animal model that recapitulates key as-
FIG 1 Analysis of the effect of semen on vaginal cell-free HIV-1 transmission
and on the protective effect of topically administered maraviroc. Symbols in
the top and middle panels: open blue squares, semen, infection negative (n 
3); solid blue squares, semen, infection positive (n  6); open red circles,
vehicle, infection negative (n  1); solid red circles, vehicle, infection positive
(n  5); green diamonds, top panel, maraviroc plus semen (n  6), and
bottom panel, maraviroc treated (n  6). BLT humanized mice were exposed
vaginally to HIV-1JR-CSF (7.0  10
5 TCIU) in the presence (n  9) or absence
(n  6) of human semen and in the presence of semen and maraviroc (5 mM).
(Top panel) Infection was determined based on the presence or absence of
viral RNA in plasma over the course of the experiment. Transmission in the
vehicle-treated mice was 5/6, in the mice receiving virus resuspended in semen,
6/9 were positive, and in the mice receiving virus resuspended in semen after
maraviroc administration, 0/6 were positive for viral RNA. LOD, limit of de-
tection. (Middle panel) Longitudinal analysis of peripheral blood CD4 T cell
levels of infected and noninfected mice. Symbols in the bottom panel: solid
green line, maraviroc plus semen (n  6); solid blue line, semen (n  9);
dashed red line, vehicle (n  6). Statistical analysis was performed using the
Mantel-Cox log-rank test. Over the course of the experiment, all six maravi-
roc-treated mice remained HIV negative (P  0.01). The indicated error bars
represent the standard deviations.
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pects of HIV infection in humans, including mucosal HIV-1 in-
fection (21–24). While the semen and immune cells in BLT mice
are human, the remainder of the female reproductive tract (FRT)
is murine. In studies of conception, semen interacts with cells in
the FRT to invoke inflammation and then tolerance in prepara-
tion for implantation. Some of these interactions take place be-
tween semen and the cervicovaginal epithelium. In this transmis-
sion model, some of cells exposed to semen would be murine
epithelial in origin. It is therefore possible that interactions be-
tween the human semen and murine epithelium might not fully
emulate the effects of semen in the human FRT. However, even
though most mouse cytokines do not act on human receptors, it
should be noted that most human cytokines do act on the mouse
receptors (25).
In this article, we took advantage of the utility of the BLT model
to investigate the possible effect of semen in vaginal HIV trans-
mission. Vaginal HIV transmission in BLT mice has been exten-
sively documented (5–7, 26). BLT humanized mice can be effi-
ciently infected by HIV after a single vaginal inoculation, without
the need for any hormonal treatment (5–7, 26), and mucosal HIV
transmission in this model can be efficiently prevented by sys-
temic or topically applied antivirals and microbicides (5–7). It is
important to note that none of these previous reports using any
type of humanized mouse model has used human semen in their
experimental design. This study, to our knowledge represents the
first comprehensive in vivo analysis of human semen on vaginal
HIV-1 transmission. Furthermore, both cell-free, cell-associated,
and transmitted/founder viruses were evaluated in the presence of
semen, lending breadth to the impact of this study on future in-
FIG 2 Vaginal infection of BLT humanized mice with HIV-1CH040, a trans-
mitted/founder virus, in the presence of semen. Symbols in the top and middle
panels: solid blue squares, semen (n  6); solid red circles, vehicle (n  4). BLT
humanized mice were exposed vaginally to the transmitted/founder CCR5-
tropic HIV-1 isolate CH040 in the presence (50%) (n  6) or absence (n  4)
of human semen. Plasma viral loads (top) and circulating CD4 T cell levels
(middle) were monitored longitudinally. (Bottom panel) Symbols: solid blue
line, semen (n  6); dashed red line, vehicle (n  4). There was no statistical
difference in the transmission of HIV-1CH040 in the presence or absence of
semen (P  0.8). All mice in both groups became infected 2 weeks postexpo-
sure (bottom). Statistical analysis was performed using a Mantel-Cox log-rank
test. The indicated error bars represent the standard deviation.
FIG 3 Efficient transmission of cell-associated HIV-1JR-CSF in the presence of
semen. Symbols in the top and middle panels: solid blue squares, semen, in-
fection positive (n  3); solid red circles, vehicle, infection positive (n  4);
open blue squares, semen, infection negative (n  1). BLT humanized mice
were exposed vaginally to 1.0  105 HIV-1JR-CSF Gag p24
 cells in the presence
(n  4) or absence (n  4) of human semen. Infection was determined by the
presence or absence of plasma viral RNA. Plasma viral load and circulating
CD4 T cell levels were monitored longitudinally (top and middle panels,
respectively). Symbols in the bottom panel: solid blue line, semen (n  4);
dashed red line, vehicle (n  4). Similar levels of vaginal transmission were
observed in the presence or absence of human semen (P  0.5) (bottom).
Statistical analysis was performed using a Mantel-Cox log-rank test. The indi-
cated error bars represent the standard deviation.
Council et al.
7850 aac.asm.org December 2015 Volume 59 Number 12Antimicrobial Agents and Chemotherapy
vestigations. Second, this study impacts continuing efforts to de-
velop topically applied microbicides. In showing that a topically
administered 5 mM maraviroc solution is able to completely pre-
vent transmission in this model, we are able to present maraviroc
as an attractive candidate for further in vivo testing.
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